Researchers examined 70,718 people diagnosed with Alzheimer’s disease in Finland and compared their opioid use to 282,862 controls, from 2005 to 2011.
The study shows long-term use of opioids does not increase Alzheimer’s disease risk, and neither does higher cumulative opioid doses.
Researchers noted several other adverse effects related to opioids, ranging from drowsiness to addiction.
More articles on opioids:
Georgia’s most populated county files opioid epidemic lawsuit
FDA Commissioner: Due to previous inaction by the FDA, combating the opioid crisis will ‘be far more dramatic’
AHA launches toolkit to address opioid epidemic
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
